Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Cleaning and Disinfection of Dosing Rooms – V 2.0

Posted on By

BA-BE Studies: SOP for Cleaning and Disinfection of Dosing Rooms – V 2.0

Standard Operating Procedure for Cleaning and Disinfection of Dosing Rooms in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/118/2025
Supersedes SOP/BA-BE/118/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the standardized cleaning and disinfection procedures for dosing rooms used in BA/BE studies to maintain aseptic conditions, minimize cross-contamination, and comply with applicable GCP and hygiene standards.

2. Scope

This SOP applies to all dosing rooms within the clinical unit where investigational products are administered to study volunteers. It includes procedures for pre-dose, post-dose, and scheduled deep cleaning activities.

3. Responsibilities

  • Housekeeping Personnel: Perform cleaning and disinfection as per defined schedule using approved cleaning agents.
  • Clinical Research Coordinator: Verifies cleanliness before volunteer entry and after dosing procedures.
  • QA Officer: Conducts periodic audits and reviews cleaning records.
  • Facility Supervisor: Ensures availability of cleaning supplies and trained staff.
See also  BA-BE Studies: SOP for Handling Serious Adverse Events (SAEs) - V 2.0

4. Accountability

The Head of Clinical Facility Operations is accountable for ensuring that dosing rooms remain compliant with hygiene protocols and ready for study use at all times.

5. Procedure

5.1 Types of Cleaning

  1. Routine Cleaning: Conducted before and after each dosing session.
  2. Deep Cleaning: Conducted weekly or after any spill, contamination, or unplanned event.

5.2 Cleaning Agents and Materials

  1. Use only approved disinfectants (e.g., 70% IPA, hypochlorite solution 0.5%, or quaternary ammonium compounds).
  2. Ensure availability of:
    • Disposable gloves
    • Face masks
    • Clean mop and lint-free wipes
    • Yellow/red waste bins for disposal

5.3 Routine Cleaning Procedure

  1. Wear PPE before entering the dosing room.
  2. Wipe all surfaces (beds, tables, dosing counters, IV stands) with 70% IPA.
  3. Disinfect floors starting from farthest corner to exit using freshly prepared disinfectant solution.
  4. Empty waste bins and dispose of used PPE and materials in designated biomedical waste containers.
  5. Document in Annexure-1: Dosing Room Cleaning Log.
See also  BA-BE Studies: SOP for Preparing Clinical Investigator’s Brochure (CIB) - V 2.0

5.4 Deep Cleaning Procedure

  1. Remove all equipment and wipe down walls, fixtures, air vents, and high-contact surfaces.
  2. Use fumigation or fogging if directed by QA during spill or contamination events.
  3. Replace bed linens, curtains, and disposable drapes.
  4. Document activity in Annexure-2: Dosing Room Deep Cleaning Record.

5.5 Cleaning Validation and Spot Checks

  1. QA shall conduct random swab testing (optional based on policy) for surface hygiene.
  2. Audit housekeeping logs weekly using Annexure-3: QA Cleaning Audit Sheet.

5.6 Post-Cleaning Readiness Check

  1. Clinical Research Coordinator to inspect and confirm readiness using Annexure-4: Pre-Dosing Room Clearance Checklist.
  2. No volunteer entry shall be allowed without documented clearance.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • QA: Quality Assurance
  • PPE: Personal Protective Equipment
  • IPA: Isopropyl Alcohol
  • SOP: Standard Operating Procedure

7. Documents

  1. Dosing Room Cleaning Log – Annexure-1
  2. Dosing Room Deep Cleaning Record – Annexure-2
  3. QA Cleaning Audit Sheet – Annexure-3
  4. Pre-Dosing Room Clearance Checklist – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • WHO Guidelines for Good Hygiene Practices
  • Biomedical Waste Management Rules – India
See also  BA-BE Studies: SOP for Project Risk Identification and Mitigation - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Dosing Room Cleaning Log

Date Time Area Cleaned Performed By Verified By
17/04/2025 07:30 AM Room A Sunita Reddy Rajesh Kumar

Annexure-2: Dosing Room Deep Cleaning Record

Date Type Agent Used Performed By Remarks
15/04/2025 Fogging Hydrogen Peroxide Ajay Verma Completed

Annexure-3: QA Cleaning Audit Sheet

Date QA Auditor Area Audited Observations Corrective Actions
16/04/2025 Meena Joshi Room B Surface streaks Re-cleaned

Annexure-4: Pre-Dosing Room Clearance Checklist

Room Inspected By Date Checkpoints Cleared Ready for Use
Dose Room C Rajesh Kumar 17/04/2025 Yes Yes

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Release Regulatory Requirement QA Head
17/04/2025 2.0 Enhanced procedures, added readiness checklist Annual Review QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Elixir Department: SOP for Recording Dispensed Quantities in BMR – V 2.0
Next Post: Aerosol: SOP for Change Control in Equipment Validation – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version